Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free BCT Stock Alerts

BriaCell Therapeutics (BCT) Competitors

BriaCell Therapeutics logo
C$4.85 -0.08 (-1.62%)
As of 08/6/2026 03:47 PM Eastern
Compare

BCT vs. IPA, HBP, SCYB, COM, and NVH

Should you buy BriaCell Therapeutics stock or one of its competitors? MarketBeat compares BriaCell Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BriaCell Therapeutics include ImmunoPrecise Antibodies (IPA), Helix BioPharma (HBP), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), and Novoheart (NVH). These companies are all part of the "biotechnology" industry.

How does BriaCell Therapeutics compare to ImmunoPrecise Antibodies?

ImmunoPrecise Antibodies (CVE:IPA) and BriaCell Therapeutics (TSE:BCT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

BriaCell Therapeutics has lower revenue, but higher earnings than ImmunoPrecise Antibodies. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunoPrecise AntibodiesC$19.47M8.33-C$22.19M-C$0.89N/A
BriaCell TherapeuticsN/AN/A-C$2.37M-C$0.84N/A

ImmunoPrecise Antibodies' return on equity of 0.00% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ImmunoPrecise AntibodiesN/A N/A N/A
BriaCell Therapeutics N/A -147.92%-122.71%

0.0% of BriaCell Therapeutics shares are owned by institutional investors. 9.3% of BriaCell Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, ImmunoPrecise Antibodies' average media sentiment score of 0.00 equaled BriaCell Therapeutics'average media sentiment score.

Company Overall Sentiment
ImmunoPrecise Antibodies Neutral
BriaCell Therapeutics Neutral

Summary

BriaCell Therapeutics beats ImmunoPrecise Antibodies on 5 of the 8 factors compared between the two stocks.

How does BriaCell Therapeutics compare to Helix BioPharma?

Helix BioPharma (TSE:HBP) and BriaCell Therapeutics (TSE:BCT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Helix BioPharma is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A
BriaCell TherapeuticsN/AN/A-C$2.37M-C$0.84N/A

In the previous week, Helix BioPharma's average media sentiment score of 0.00 equaled BriaCell Therapeutics'average media sentiment score.

Company Overall Sentiment
Helix BioPharma Neutral
BriaCell Therapeutics Neutral

Helix BioPharma has a beta of 0.433836, indicating that its share price is 57% less volatile than the broader market. Comparatively, BriaCell Therapeutics has a beta of 1.96435, indicating that its share price is 96% more volatile than the broader market.

0.0% of Helix BioPharma shares are held by institutional investors. Comparatively, 0.0% of BriaCell Therapeutics shares are held by institutional investors. 2.2% of Helix BioPharma shares are held by insiders. Comparatively, 9.3% of BriaCell Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Helix BioPharma's return on equity of -21.54% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -21.54% -279.98%
BriaCell Therapeutics N/A -147.92%-122.71%

Summary

BriaCell Therapeutics beats Helix BioPharma on 6 of the 8 factors compared between the two stocks.

How does BriaCell Therapeutics compare to Scythian Biosciences?

BriaCell Therapeutics (TSE:BCT) and Scythian Biosciences (CVE:SCYB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

Scythian Biosciences' return on equity of 0.00% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BriaCell TherapeuticsN/A -147.92% -122.71%
Scythian Biosciences N/A N/A N/A

In the previous week, BriaCell Therapeutics' average media sentiment score of 0.00 equaled Scythian Biosciences'average media sentiment score.

Company Overall Sentiment
BriaCell Therapeutics Neutral
Scythian Biosciences Neutral

0.0% of BriaCell Therapeutics shares are owned by institutional investors. 9.3% of BriaCell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A-C$2.37M-C$0.84N/A
Scythian BiosciencesN/AN/AN/AN/AN/A

Summary

BriaCell Therapeutics and Scythian Biosciences tied by winning 2 of the 4 factors compared between the two stocks.

How does BriaCell Therapeutics compare to 138267 (COM.TO)?

BriaCell Therapeutics (TSE:BCT) and 138267 (COM.TO) (TSE:COM) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

0.0% of BriaCell Therapeutics shares are owned by institutional investors. 9.3% of BriaCell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

138267 (COM.TO)'s return on equity of 0.00% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BriaCell TherapeuticsN/A -147.92% -122.71%
138267 (COM.TO) N/A N/A N/A

In the previous week, BriaCell Therapeutics' average media sentiment score of 0.00 equaled 138267 (COM.TO)'saverage media sentiment score.

Company Overall Sentiment
BriaCell Therapeutics Neutral
138267 (COM.TO) Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A-C$2.37M-C$0.84N/A
138267 (COM.TO)N/AN/AN/AN/AN/A

Summary

BriaCell Therapeutics and 138267 (COM.TO) tied by winning 2 of the 4 factors compared between the two stocks.

How does BriaCell Therapeutics compare to Novoheart?

BriaCell Therapeutics (TSE:BCT) and Novoheart (CVE:NVH) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

Novoheart's return on equity of 0.00% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BriaCell TherapeuticsN/A -147.92% -122.71%
Novoheart N/A N/A N/A

0.0% of BriaCell Therapeutics shares are held by institutional investors. 9.3% of BriaCell Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, BriaCell Therapeutics' average media sentiment score of 0.00 equaled Novoheart'saverage media sentiment score.

Company Overall Sentiment
BriaCell Therapeutics Neutral
Novoheart Neutral

BriaCell Therapeutics has higher earnings, but lower revenue than Novoheart. Novoheart is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A-C$2.37M-C$0.84N/A
NovoheartC$423.50K236.08-C$7.17M-C$0.04N/A

Summary

BriaCell Therapeutics and Novoheart tied by winning 4 of the 8 factors compared between the two stocks.

Get BriaCell Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BCT vs. The Competition

Export
MetricBriaCell TherapeuticsBiotechnology IndustryHealthcare SectorTSE Exchange
Market CapC$42.20MC$3.61BC$6.95BC$12.52B
Dividend Yield13.70%3.77%2.59%6.20%
P/E Ratio-5.778.32270.8234.29
Price / SalesN/A1,294.25600.159.84
Price / CashN/A101.3771.8982.29
Price / Book1.5017.6413.004.50
Net Income-C$2.37M-C$13.22MC$3.46BC$299.09M
7 Day Performance0.62%4.45%3.39%2.56%
1 Month Performance-1.42%-4.89%-2.69%1.57%
1 Year Performance-50.00%56.58%75.98%33.86%

BriaCell Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BCT
BriaCell Therapeutics
N/AC$4.85
-1.6%		N/A-42.3%C$42.20MN/AN/A16
IPA
ImmunoPrecise Antibodies
N/AC$6.50
+0.8%		N/A+0.0%C$162.08MC$19.47MN/A80
HBP
Helix BioPharma
N/AC$1.50
+3.4%		N/A+43.5%C$114.57MN/AN/A9
SCYB
Scythian Biosciences
N/AC$3.49
-5.9%		N/A+0.0%C$102.38MN/AN/AN/A
COM
138267 (COM.TO)
N/AN/AN/AN/AC$102.19MN/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:BCT) was last updated on 8/7/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel